2
ALL2
Quantum Leap HealthcareYear
2
ALL1
20211
2020DEALS // DEV.
2
ALL2
DevelopmentsCountry
2
ALL2
U.S.A2
ALL2
InapplicableTherapeutic Area
2
ALL2
Infections and Infectious DiseasesStudy Phase
2
ALL2
Phase IIDeal Type
2
ALL2
InapplicableProduct Type
2
ALL2
Other Small MoleculeDosage Form
2
ALL2
UndisclosedLead Product
2
ALL2
Cenicriviroc SulfoneTarget
2
ALL2
CCR5Lead Product(s) : Cenicriviroc Sulfone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The I-SPY COVID Trial identified the initial agents for the study through a unique partnership with the COVID R&D Alliance, and CVC was the first oral agent identified and approved to go forward through this mechanism.
Product Name : TBR-652
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2021
Lead Product(s) : Cenicriviroc Sulfone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cenicriviroc Sulfone,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The I-SPY COVID Trial utilizes Quantum Leap Healthcare Collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments.
Product Name : TBR-652
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2020
Lead Product(s) : Cenicriviroc Sulfone,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable